Singh B
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA. singh.balwinder@mayo.edu.
ArticleKetamine
Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.
ArticleKetamine
Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial.
ArticleKetamine
Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.
ArticleKetamine
Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.
ArticleKetamine
Question: What Are the Management Options for Treatment-Resistant Bipolar Disorder With Recurrent Mood Switches Despite Being on Clozapine, Lithium, Lamotrigine, and Ketamine?
ArticleKetamine
Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel.
ArticlePsilocybin
Psilocybin and Bipolar Depression: Promise and Prudence.
ArticleKetamine
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis.
ArticleKetamine
Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study.
ArticleKetamine
Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study.
ArticleKetamine
Bipolar disorder.
ArticleLSD
Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function.
ArticleKetamine
Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.
ArticleKetamine
Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression.
ArticleKetamine
Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder.
ArticleMDMA
MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward.
ArticleKetamine
Ketamine and Esketamine for Depression in Daily Practice: Opportunities and Challenges.
ArticleKetamine
Editorial: Perspectives on new fast-acting antidepressants.
ArticleKetamine
Intravenous (IV) ketamine versus intranasal esketamine for depression- Advantage IV ketamine?
ArticleKetamine
Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
ArticleKetamine
Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review.
ArticleKetamine
Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
ArticleKetamine
Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression.
ArticleKetamine
An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis.
ArticleKetamine
Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report.
ArticleKetamine
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
ArticleKetamine